Instrument Inactif

Autres langues Blue Water Ventures International Inc Other OTC

Actions

US8317182009

Recherche biotechnologique et médicale

Cours en clôture Other OTC
- ^USD	-

12/12/23	Psycheceutical Bioscience, Inc. annonce des changements au sein de son conseil d'administration	CI
12/12/23	Psycheceutical Bioscience, Inc. nomme Neilank K. Jha comme nouveau président exécutif	CI

Autres langues

03/08	GMO Internet Group to Field a Group-Wide Team at 'DEF CON 34' CTF, the World's Premier Cybersecurity Competition
16/05	Maha and BWIV terminate the Letter of Intent for proposed SPAC transaction
01/10/25	Blue Water pitches $10bn offer for Citgo in Delaware court
16/09/25	Delaware court opens Venezuela’s Citgo sale battle as creditors vie for control
09/09/25	Blue Water bids $10bn for Venezuela’s Citgo, offers bondholders cash and equity
08/09/25	Blue Water Acquisition Corp. III Announces Submission of $10 Billion Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.
31/07/25	Blue Water Suriname secures contract to support Noble Corporation drilling operations
20/06/24	Blue Water Ventures International, Inc. announced that it expects to receive $10 million in funding
12/12/23	Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes
12/12/23	Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman
26/09/23	Blue Water Ventures International, Inc. announced that it expects to receive $5 million in funding
13/07/23	Psycheceutical Bioscience, Inc Announces First Patient Has Been Dosed in Its Phase I Study to Evaluate Its Patented Neurodirectâ„¢ Ketamine Topical Delivery System for the Treatment of Post Traumatic Stress Disorder
21/04/23	Veru Sells ENTADFI Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
13/04/23	Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review
29/03/23	Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
21/03/23	Psycheceutical Bioscience, Inc. Announces Publication of Pre-Clinical Observational Data Supports Potential of its NeuroDirect™ Ketamine Topical Cream as Treatment for PTSD
21/03/23	Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
21/03/23	Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
15/02/23	Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
15/02/23	Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
15/02/23	Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
02/02/23	Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
02/02/23	Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
26/01/23	Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
26/01/23	Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD